Radiotherapy & Oncology
Volume 86, Issue 1 , Pages 14-19, January 2008

Antiproton radiotherapy

  • Niels Bassler

      Affiliations

    • Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark
    • Deutsches Krebsforschungszentrum, Heidelberg, Germany
    • Corresponding Author InformationCorresponding author. Niels Bassler, Deutsches Krebsforschungszentrum, E0409, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
  • ,
  • Jan Alsner

      Affiliations

    • Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark
  • ,
  • Gerd Beyer

      Affiliations

    • Hospital Universitaire de Geneve, Geneva, Switzerland
  • ,
  • John J. DeMarco

      Affiliations

    • David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
  • ,
  • Michael Doser

      Affiliations

    • CERN, Geneva, Switzerland
  • ,
  • Dragan Hajdukovic

      Affiliations

    • University of Montenegro, Podgorica, Montenegro
  • ,
  • Oliver Hartley

      Affiliations

    • Hospital Universitaire de Geneve, Geneva, Switzerland
  • ,
  • Keisuke S. Iwamoto

      Affiliations

    • David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
  • ,
  • Oliver Jäkel

      Affiliations

    • Deutsches Krebsforschungszentrum, Heidelberg, Germany
  • ,
  • Helge V. Knudsen

      Affiliations

    • Department of Physics and Astronomy, and
  • ,
  • Sandra Kovacevic

      Affiliations

    • University of Montenegro, Podgorica, Montenegro
  • ,
  • Søren Pape Møller

      Affiliations

    • ISA, University of Aarhus, Aarhus, Denmark
  • ,
  • Jens Overgaard

      Affiliations

    • Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark
  • ,
  • Jørgen B. Petersen

      Affiliations

    • Department of Medical Physics, Aarhus University Hospital, Aarhus, Denmark
  • ,
  • Timothy D. Solberg

      Affiliations

    • University of Nebraska Medical Center, Omaha, NE, USA
  • ,
  • Brita S. Sørensen

      Affiliations

    • Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark
  • ,
  • Sanja Vranjes

      Affiliations

    • VINCA Institute for Nuclear Sciences, Belgrade, Serbia
  • ,
  • Bradly G. Wouters

      Affiliations

    • University of Maastricht, Res. Institute Growth and Development, The Netherlands
  • ,
  • Michael H. Holzscheiter

      Affiliations

    • University of New Mexico, Albuquerque, NM, USA

Received 24 September 2007; received in revised form 13 November 2007; accepted 28 November 2007. published online 03 January 2008.

Abstract 

Antiprotons are interesting as a possible future modality in radiation therapy for the following reasons: When fast antiprotons penetrate matter, protons and antiprotons have near identical stopping powers and exhibit equal radiobiology well before the Bragg-peak. But when the antiprotons come to rest at the Bragg-peak, they annihilate, releasing almost 2GeV per antiproton–proton annihilation. Most of this energy is carried away by energetic pions, but the Bragg-peak of the antiprotons is still locally augmented with ∼20–30MeV per antiproton. Apart from the gain in physical dose, an increased relative biological effect also has been observed, which can be explained by the fact that some of the secondary particles from the antiproton annihilation exhibit high-LET properties. Finally, the weakly interacting energetic pions, which are leaving the target volume, may provide a real time feedback on the exact location of the annihilation peak.

We have performed dosimetry experiments and investigated the radiobiological properties using the antiproton beam available at CERN, Geneva. Dosimetry experiments were carried out with ionization chambers, alanine pellets and radiochromic film. Radiobiological experiments were done with V79 WNRE Chinese hamster cells. The radiobiological experiments were repeated with protons and carbon ions at TRIUMF and GSI, respectively, for comparison. Several Monte Carlo particle transport codes were investigated and compared with our experimental data obtained at CERN. The code that matched our data best was used to generate a set of depth dose data at several energies, including secondary particle-energy spectra. This can be used as base data for a treatment planning software such as TRiP.

Our findings from the CERN experiments indicate that the biological effect of antiprotons in the plateau region may be reduced by a factor of 4 for the same biological target dose in a spread-out Bragg-peak, when comparing with protons.

The extension of TRiP to handle antiproton beams is currently in progress. This will enable us to perform planning studies, where the potential clinical consequences can be examined, and compared to those of other beam modalities such as protons, carbon ions, or IMRT photons.

Keywords: Antiproton, RBE, Particle irradiation

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0167-8140(07)00634-2

doi:10.1016/j.radonc.2007.11.028

Radiotherapy & Oncology
Volume 86, Issue 1 , Pages 14-19, January 2008